Chronic Inhibition of 11<i>β</i>-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome

<table>The change in body weight from baseline in obese and lean SHR-cp during three weeks of vehicle or compound 11 administration (10 mg/kg/d). </table>

BioMed Research International

fig3

Figure 3

Figure 3: Chronic Inhibition of 11<i>β</i>-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome 

Figure 3 | Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome 